• Exelixis Inc., of South San Francisco, reported net product revenue for Cometriq (cabozantinib) totaling $4 million for the second quarter. The drug gained approval late last year for medullary thyroid cancer, though the company is looking to expand its use in larger indications, with Phase III studies ongoing in metastatic renal cell carcinoma and castration-resistant prostate cancer.